ReutersSeptember 30, 2026Trial readout
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial
Reported by Reuters. Read the original →
What the story says
A trial reported that Regeneron's weight-loss drug, when combined with Novo's semaglutide, resulted in a reduction of muscle loss by half.
Summarised by a model from Reuters's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
SemaglutideA · Human clinical
- Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial.Human · RCT · 2026
- Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?Human · RCT · 2026
- Complex clinical encounter series: Glucagon-like peptide-1 receptor agonists-induced weight loss: are we paying attention to bone health?Human · Case report · 2026
What the headline doesn't tell you
- Semaglutide has 60 studies on file, 32 of them in humans, the newest published 2026.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.